Loading publications…
The last 5 uploaded publications
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, P. Abada, Masatoshi Kudo (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), pp. 282-296, DOI: 10.1016/s1470-2045(18)30937-9.
Article146 days agoREACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Ho Yeong Lim, Marc Pracht, Kun‐Ming Rau, Philippe Merle, Kenta Motomura, Izumi Ohno, Bruno Daniele, Dongbok Shin, Guido Gerken, Paolo Abada, Yanzhi Hsu, Masatoshi Kudo (2018). REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.. Journal of Clinical Oncology, 36(15_suppl), pp. 4003-4003, DOI: 10.1200/jco.2018.36.15_suppl.4003.
Article146 days agoSerum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo (2021). Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 124(8), pp. 1388-1397, DOI: 10.1038/s41416-021-01260-w.
Article146 days agoRamucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2
Masatoshi Kudo, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Arndt Vogel, Kenta Motomura, Éric Assenat, Philippe Merle, Giovanni Brandi, Bruno Daniele, Takuji Okusaka, Jiří Tomášek, Christophe Borg, Vincenzo Dadduzio, Manabu Morimoto, Marc Pracht, Min‐Hua Jen, N. Drove Ubreva, Ryan C. Widau, Kenta Shinozaki, Reigetsu Yoshikawa, Andrew X. Zhu (2020). Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2. Liver International, 40(8), pp. 2008-2020, DOI: 10.1111/liv.14462.
Article146 days agoRamucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.
Richard S. Finn, Masatoshi Kudo, Yoon‐Koo Kang, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Ho Yeong Lim, Marc Pracht, Kun Ming Rau, Philippe Merle, Kenta Motomura, Izumi Ohno, Bruno Daniele, Dongbok Shin, Guido Gerken, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu (2019). Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline α-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.. Journal of Clinical Oncology, 37(4_suppl), pp. 326-326, DOI: 10.1200/jco.2019.37.4_suppl.326.
Article146 days ago